Journal of pain and symptom management
-
J Pain Symptom Manage · Jun 2005
Comparative StudyChanges in medical and nursing care in cancer patients transferred from a palliative care team to a palliative care unit.
The primary aim of this study was to explore the changes in medical/nursing care in patients who transferred from a palliative care team (PCT) to a palliative care unit (PCU) in the same hospital, and to explore the reasons why new or modified interventions were required. This was a retrospective study of 50 consecutive patients who were transferred from PCT to PCU in a 750-bed general hospital. A trained nurse performed a chart review and recorded the changes in 1) medical/nursing care, 2) help with decision-making within 48 hours after PCU admission, and 3) documentation of family and psycho-existential care. ⋯ The chief reasons for these changes were: under-recognition of the problems and unavailability of treatments (pharmacological treatments), no intention to intervene and recommendations not followed by primary physicians (rehydration therapy), no intention to intervene (nursing care), and no intention to intervene and under-recognition of the problems (help with decision-making). These data demonstrate that many patients under PCT consultation receive new or modified interventions after PCU admission. Potentially useful strategies to strengthen the PCT interventions are: modification of intervention structure to minimize under-recognition of symptoms and decision making problems (e.g., use of standardized assessment tools, regular conferences), changes in the health care system to allow unlicensed drugs, clinical studies to clarify the benefits of artificial hydration therapy, and greater efforts to intervene in the areas of nursing care, help with decision making, family care, and psycho-existential care.
-
J Pain Symptom Manage · Jun 2005
Comparative StudyDiscrepancies and similarities in how patients with lung cancer and their professional and family caregivers assess symptom occurrence and symptom distress.
Historically, conceptual distinctions have not been made between the components of symptom experience--symptom distress and symptom occurrence--nor has the question of how distressing patients perceive different symptoms to be, irrespective of their current occurrence, been addressed. The aim of this study was to explore the hypothesis that there may be different patterns in discrepancies between how lung cancer patients and their caregivers assess symptom distress and in how they assess symptom occurrence. Thirty-three patient-nurse dyads and 54 patient-family caregiver dyads assessed patients' symptom distress and symptom occurrence. ⋯ Patients and caregivers were more in agreement about which symptoms might cause distress than about current symptom occurrence. Caregivers rated symptom occurrence as greater than patients. The findings highlight the need to further explore what symptom characteristics caregivers address when assessing patients' symptom experiences.
-
J Pain Symptom Manage · Jun 2005
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialComparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials.
Two multicenter, randomized, double-blind, crossover studies with identical designs evaluated the efficacy of oral extended-release hydromorphone (HHER) administered q24h compared with immediate-release hydromorphone (HHIR) dosed four times daily in patients with persistent moderate to severe pain. Patients titrated to a stable HHER dose were randomized to individualized doses of HHER or HHIR for 3 to 7 days before crossover to the second treatment. Primary efficacy end point was the mean of average pain intensity (API) scores, rated on a 0- to 10-point numeric scale, over the last 2 days before the pharmacokinetics/pharmacodynamics day of each double-blind period. ⋯ No reduction in pain control occurred in patients administered HHER at the end of the 24-hour dosing period. Most treatment-emergent adverse events were opioid-related. In these studies, HHER administered q24h and HHIR dosed four times daily provided comparable analgesia at an equivalent total daily dose.
-
J Pain Symptom Manage · Jun 2005
Randomized Controlled Trial Comparative Study Clinical TrialNebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study.
This study compared the effects of nebulized versus subcutaneous morphine on the intensity of dyspnea in cancer patients. Patients with a resting dyspnea intensity > or =3 on a 0-10 scale (0=no dyspnea, 10=worst possible dyspnea) who received regular oral or parenteral opioids were included. On day 1, patients received either subcutaneous (SC) morphine plus nebulized placebo or nebulized morphine plus SC placebo. ⋯ Unfortunately, due to limited sample size, there was insufficient power to rule out a significant difference between both routes of administration. Nebulized morphine offered dyspnea relief similar to that of SC morphine. Larger randomized controlled trials in patients with both continuous dyspnea and earlier stages of dyspnea are justified.
-
J Pain Symptom Manage · Jun 2005
Pilot of a pathway to improve the care of imminently dying oncology inpatients in a Veterans Affairs Medical Center.
We report on the implementation of a previously developed clinical pathway for terminally ill patients, Palliative Care for Advanced Disease (PCAD), on a Veterans Administration (VA) acute care oncology unit, comparing processes of care and outcomes for patients on and off the pathway. The PCAD pathway is designed to identify imminently dying patients, review care goals, respect patients' wishes, assess and manage symptoms, address spirituality, and support family members. Retrospective chart reviews from 15 patients who died on PCAD, 14 patients who died on general wards during the same time, and 10 oncology unit patients who died prior to PCAD revealed that PCAD patients were more likely to have documentation of care goals and plans of comfort care (P=0.0001), fewer interventions, and more symptoms assessed (P=0.004), and more symptoms managed according to PCAD guidelines (P=0.02). Implementation of PCAD improved care of dying inpatients by increasing documentation of goals and plans of care, improving symptom assessment and management, and decreasing interventions at the end of life.